These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

34 related articles for article (PubMed ID: 10360604)

  • 1. Inhibitors of the Cancer Target Ribonucleotide Reductase, Past and Present.
    Huff SE; Winter JM; Dealwis CG
    Biomolecules; 2022 Jun; 12(6):. PubMed ID: 35740940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [New antitumor antimetabolites--gemcitabine and DMDC].
    Matsui K; Fukuoka M
    Gan To Kagaku Ryoho; 1992 Nov; 19(13):2127-32. PubMed ID: 1332622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pharmacologic approach to dosage intensification.
    Weiss AJ
    Sel Cancer Ther; 1990; 6(3):129-34. PubMed ID: 2281202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I and pharmacologic study of oral (E)-2'-deoxy-2'-(fluoromethylene) cytidine: on a daily x 5-day schedule.
    Masuda N; Negoro S; Takeda K; Takifuji N; Hirashima T; Yana T; Kurata N; Kuwabara T; Kobayashi S; Kudoh S; Matsui K; Takada M; Fukuoka M
    Invest New Drugs; 1998-1999; 16(3):245-54. PubMed ID: 10360604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of oral 2'-deoxy-2'-methylidenecytidine: on a daily x 14-day schedule.
    Masuda N; Matsui K; Yamamoto N; Nogami T; Nakagawa K; Negoro S; Takeda K; Takifuji N; Yamada M; Kudoh S; Okuda T; Nemoto S; Ogawa K; Myobudani H; Nihira S; Fukuoka M
    Clin Cancer Res; 2000 Jun; 6(6):2288-94. PubMed ID: 10873079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I clinical trials of tezacitabine [(E)-2'-deoxy-2'-(fluoromethylene)cytidine] in patients with refractory solid tumors.
    Rodriguez GI; Jones RE; Orenberg EK; Stoltz ML; Brooks DJ
    Clin Cancer Res; 2002 Sep; 8(9):2828-34. PubMed ID: 12231523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The ribonucleoside diphosphate reductase inhibitor (E)-2'-deoxy-(fluoromethylene)cytidine as a cytotoxic radiosensitizer in vitro.
    Coucke PA; Decosterd LA; Li YX; Cottin E; Chen X; Sun LQ; Stern S; Paschoud N; Denekamp J
    Cancer Res; 1999 Oct; 59(20):5219-26. PubMed ID: 10537300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I clinical and pharmacokinetic study of CS-682 administered orally in advanced malignant solid tumors.
    Delaunoit T; Burch PA; Reid JM; Camoriano JK; Kobayash T; Braich TA; Kaur JS; Rubin J; Erlichman C
    Invest New Drugs; 2006 Jul; 24(4):327-33. PubMed ID: 16502355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
    Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
    Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I study of a 24 hour infusion of gemcitabine in previously untreated patients with inoperable non-small-cell lung cancer.
    Anderson H; Thatcher N; Walling J; Hansen H
    Br J Cancer; 1996 Aug; 74(3):460-2. PubMed ID: 8695365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A ribonucleotide reductase inhibitor, MDL 101,731, induces apoptosis and elevates TRPM-2 mRNA levels in human prostate tumor xenografts.
    Wright PS; Cross-Doersen D; Th'ng JP; Guo XW; Crissman HA; Bradbury EM; Montgomery LR; Thompson FY; Loudy DE; Johnston JO; Bitonti AJ
    Exp Cell Res; 1996 Jan; 222(1):54-60. PubMed ID: 8549673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo inhibition of glioblastoma and neuroblastoma with MDL101731, a novel ribonucleoside diphosphate reductase inhibitor.
    Piepmeier JM; Rabidou N; Schold SC; Bitonti AJ; Prakash NJ; Bush TL
    Cancer Res; 1996 Jan; 56(2):359-61. PubMed ID: 8542592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I clinical trial of gemcitabine given as an intravenous bolus on 5 consecutive days.
    O'Rourke TJ; Brown TD; Havlin K; Kuhn JG; Craig JB; Burris HA; Satterlee WG; Tarassoff PG; Von Hoff DD
    Eur J Cancer; 1994; 30A(3):417-8. PubMed ID: 8204374
    [No Abstract]   [Full Text] [Related]  

  • 14. Regression of human breast tumor xenografts in response to (E)-2'-deoxy-2'-(fluoromethylene)cytidine, an inhibitor of ribonucleoside diphosphate reductase.
    Bitonti AJ; Dumont JA; Bush TL; Cashman EA; Cross-Doersen DE; Wright PS; Matthews DP; McCarthy JR; Kaplan DA
    Cancer Res; 1994 Mar; 54(6):1485-90. PubMed ID: 8137252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study.
    Anderson H; Lund B; Bach F; Thatcher N; Walling J; Hansen HH
    J Clin Oncol; 1994 Sep; 12(9):1821-6. PubMed ID: 8083706
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.